SightGlass Vision spectacles control myopia progression for six- and seven-year-olds, according to pivotal clinical trial findings presented at an international conference earlier this week.
Spectacle lenses using patent-protected SightGlass Vision Diffusion Optics Technology incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina – a method intended to reduce myopia progression in children.
The company said analysis of 24-month interim data from the pivotal CYPRESS clinical trial is offering increased hope for controlling myopia progression among young children.
Spectacles that use SightGlass Vision Diffusion Optics Technology were shown to significantly reduce both axial length and cycloplegic spherical equivalent refraction (SER) progression in six- and seven-year-old children versus the control.
The average reduction in axial length was 0.27 mm, and 0.77 dioptres (D) in cycloplegic SER progression.
The research, Two Year Effectiveness of a Novel Myopia Management Spectacle Lens in Young Myopes, was presented for the first time at the 2022 Dutch Contact Lens Congress (NCC), which took place in The Netherlands on 26-27 June.
According to the company, the focus on age is of particular interest to eyecare professionals and researchers, as myopia progresses fastest in the youngest children.
The company said that since progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health.
Founded in 2016, SightGlass Vision now operates as a joint venture of Cooper Companies and EssilorLuxottica to accelerate commercialisation opportunities and expand the myopia management category worldwide.
Mr Andrew Sedgwick, SightGlass Vision CEO, said young myopes can be difficult to manage for many reasons.
“Parents and eyecare professionals have traditionally had a limited number of myopia control solutions for younger children,” Sedgwick said.
“Our latest analysis suggests that spectacles enabled with SightGlass Vision Diffusion Optics Technology offer a promising new approach to myopia control for six- and seven-year-olds.”
Study investigators enrolled, randomised, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada – a geographical distinction compared to most other myopia-related spectacle lens studies.
At the time of enrolment, subjects were six- to 10-years-old having myopia between -0.75 D and -4.50 D, with nearly a third being six- or seven-years-old.
With a mean age of 8.1 years at screening, the entire CYPRESS cohort is younger than children in many other well-known myopia management studies across various interventions.
The trial is now in its third year.
More reading
A myopia first: Hoya lens shows long-term efficacy
Fresh six-year MiYOSMART data unveiled at ARVO
